U.S. COVID public health emergency to stay in place
Send a link to a friend
[November 12, 2022]
By Ahmed Aboulenein and Jeff Mason
WASHINGTON (Reuters) -The United States
will keep in place the public health emergency status of the COVID-19
pandemic, allowing millions of Americans to still receive free tests,
vaccines and treatments, two Biden administration officials said on
Friday.
The possibility of a winter surge in COVID cases and the need for more
time to transition out of the public health emergency to a private
market were two factors that contributed to the decision not to end the
emergency status in January, one of the officials said.
The public health emergency was initially declared in January 2020, when
the coronavirus pandemic began, and has been renewed each quarter since
for 90 days. But the government in August began signaling it planned to
let it expire in January.
The U.S. Department of Health and Human Services (HHS) has promised to
give states 60 days' notice before letting the emergency expire, which
would have been on Friday if it did not plan on renewing it again in
January. The agency did not provide such notice, the second official
said.
Health experts believe a surge in COVID-19 infections in the United
States is likely this winter, one official said.
"We may be in the middle of one in January," he said. "That is not the
moment you want to pull down the public health emergency."
Daily U.S. cases are down to an average of nearly 41,300 as of Nov. 9,
but an average of 335 people a day are still dying from COVID, according
to the latest U.S. Centers for Disease Control and Prevention data.
Daily U.S. cases are projected to rise slowly to nearly 70,000 by
February, driven by students returning to schools and cold
weather-related indoor gatherings, the University of Washington's
Institute for Health Metrics and Evaluation said in an Oct. 21 analysis.
Deaths are forecast to remain at current levels.
The officials said a lot of work remained to be done for the transition
out of the public health emergency.
[to top of second column]
|
The word "COVID-19" is reflected in a
drop on a syringe needle in this illustration taken November 9,
2020. REUTERS/Dado Ruvic/Illustration/File Photo
The government has been paying for
COVID vaccines, some tests, and certain treatments, as well as other
care under the public health emergency (PHE) declaration. When the
emergency expires, the government will begin to transfer COVID
healthcare to private insurance and government health plans.
Health officials held large meetings with insurers and drugmakers
about moving sales and distribution of COVID vaccines and treatments
to the private sector in August and October, but none have been
publicly announced since.
"The biggest motivation from a policy perspective is ensuring a
smooth transition to the commercial market and the challenge of
unraveling the multiple protections that have been put in place,"
said Dr. Jen Kates, senior vice president at the Kaiser Family
Foundation. "Extending the PHE provides more time to manage that."
The biggest challenge is uninsured people, she said. Most Americans
have government-backed or private health insurance and are expected
to pay nothing for COVID vaccines and boosters, though they will
likely incur some out-of-pocket costs for tests and treatments.
Uninsured children will also continue to get free vaccines, but it
is unclear how they and some 25 million uninsured adults will avoid
paying the full cost of tests and treatments, and how those adults
will get vaccines.
Their number is set to grow with the emergency expiring. HHS
estimates that as many as 15 million people will lose health
coverage after a requirement by Congress that state Medicaid
programs keep people continuously enrolled expires and states return
to normal patterns for enrollment.
(Reporting by Ahmed Aboulenein and Jeff Mason in Washington; Editing
by Caroline Humer, Matthew Lewis and Rosalba O'Brien)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|